Medifirst Solutions Inc (OTC: MFST) stock skyrocketed on Monday recording a rise of 159.46% to $0.0096 at the previous close. Last week, the stock returned 84.62% versus a monthly gain of 860%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Being a development-stage company, Medifirst Solutions, Inc. concentrates on healthcare-related products for the individual- as well as professional-use markets.
Indicated for temporary relief of minor muscle and joint pain, swelling, stiffness, minor arthritis pain, muscle spasms, increase in local blood circulation, and temporary relaxation of muscles, the Time Machine Series lasers are developed by Medifirst and designed to be handled by hand.
What drove the stock?
Yesterday, MFST announced that it is financing and partnering with the upcoming real-time margin detection clinical study for breast cancer.
- Over the course of her life, one in eight American women develops invasive breast cancer.
- Breast cancer is the most frequently diagnosed cancer of American women, other than skin cancer.
- In this study researchers will evaluate the accuracy and effectiveness of a new investigational diagnostic device to be used during lumpectomy cancer surgery to reduce re-operation rates.
- Statistics show that up to 24% of women undergo a second surgery due to unclear margins.
The company said in its statement that for patients requiring surgery to remove cancer, it aims to provide the best results. Further specifics and details of the study will be announced by the company along with an overall company update in the upcoming days and weeks and an update on Time Machine Laser.